Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Why Not Target DNA? Well. . .

    There are all sorts of small-molecule drugs that bind to protein targets. Active sites of enzymes are, of course, a big subset of those, but there are plenty of enzymes whose allosteric sites are known to host synthetic ligands as well. Membrane receptor and ion channel proteins get both of those mechanisms too, and then… Read More
  • Cancer

    More Thoughts on AbbVie’s Rova-T Implosion

    I wrote a couple of months ago about the disappointing results that AbbVie had obtained with their cancer stem cell therapy “Rova-T” (rovalpituzumab tesirine) in small-cell lung cancer. This was the antibody-drug conjugate that they’d purchased from Stemcentryx – OK, let’s clarify that, they bought Stemcentryx out comp… Read More
  • Cancer

    A Glioblastoma Vaccine? Not Yet.

    If you get your biomedical breaking news from the British press, you will have heard all about a very promising vaccine treatment for glioblastoma. (“Remarkably promising” – BBC. “Could add years” – The Guardian. And there’s the Daily Mail (naturally), The Independent, and more). That would be good news, b… Read More
  • Cancer

    Cancer Sequencing Hype And Reality

    This piece in Science says something that needs to be said louder and more publicly. If you live in the US, you’ve surely seen various cancer treatment centers talking about their personalized therapy plans, and especially how they’ll tailor things to your DNA sequence and so on. You would get the impression that we have… Read More
  • Cancer

    IDO Appears to Have Wiped Out

    We have the answer to a question posed here earlier this month. That was after the Merck/Incyte failure of a combination of Keytruda and Incyte’s IDO (indole 2,3-dioxygenase) inhibitor. That mechanism was supposed to increase T-cell activity, but the trial showed it to have no effect on Keytruda’s efficacy at all. Earlier IDO trials had… Read More
  • Cancer

    Spreading Cancer (Or Just Waking It Up)

    If you look at any collection of “common myths about cancer”, you will probably find reassurances about the idea that having cancer surgery might cause the cancer to spread to other parts of the body. I remember coming across this one some years ago being surprised – I’d never heard that one myself, but it… Read More
  • Alzheimer's Disease

    Bad Investments

    Here are some sequels to stories I’ve written about here, things that have had some new chapters added to them. First off, this 2015 post mentions the steep drop in shares of Clovis Biotechnology, brought on by a rather sudden revision in the announced clinical performance of their lead drug (the covalent kinase inhibitor rociletinib). Well… Read More
  • Cancer

    IDO Inhibitors Hit a Wall

    Friday brought some very unwelcome news in oncology. I’ve written about IDO inhibitors before, partly in the context of an odd situation between Incyte and Flexus, and partly in response to a recent failed trial of a compound from NewLink. That last one shook people up a bit, but (as I mentioned in the post) Read More
  • Business and Markets

    One Of Those Binary Events for AbbVie

    Back in late 2015, I wrote about cancer stem cells, the idea that some tumors are driven by populations of slow-dividing stem cells. The theory has been that these are always going to be in there fighting against your efforts to kill off the downstream tumor cells, so unless you find a way to target… Read More
  • Business and Markets

    Pay Your Money and Hold Your Breath

    In another example of the white-knuckle here-we-go nature of the drug business, Bristol-Myers Squibb announced this morning that they’re doing a huge deal with Nektar Therapeutics for their immune stimulant drug candidate, NKTR-214. Well, actually, they’re not getting the drug, because the development deal is non-exclusive. And theyR… Read More
123...